Research programme: bithionol - Champions Oncology
Latest Information Update: 07 Apr 2011
At a glance
- Originator Southern Research Institute; Yale University
- Developer Champions Oncology
- Class Anthelmintics; Antineoplastics; Phenols; Small molecules
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Apr 2011 Champions Biotechnology is now called Champions Oncology
- 01 Apr 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 03 Nov 2010 Champions Biotechnology receives Qualifying Therapeutics Discovery Project grant from the US Department of Health and Human Services for bithionol development in Cancer